Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era

References

• Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002;2: 862–871.
   PubMed Web of Science ®Google Scholar
• Dodson S, Baracos VE, Jatoi A, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 2011;62:265–279.
   PubMed Web of Science ®Google Scholar
• Lieffers JR, Bathe OF, Fassbender K, et al. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer 2012;107:931–936.
   PubMed Web of Science ®Google Scholar
• Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998;147:755–763.
   PubMed Web of Science ®Google Scholar
• Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008;9:629–635.
   PubMed Web of Science ®Google Scholar
• Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013;31:1539–1547.
   PubMed Web of Science ®Google Scholar
• Flegal KM, Graubard BI, Williamson DF, et al. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005; 293:1861–1867.
   PubMed Web of Science ®Google Scholar
• Batsis JA, Mackenzie TA, Barre LK, et al. Sarcopenia, sarcopenic obesity and mortality in older adults: results from the National Health and Nutrition Examination Survey III. Eur J Clin Nutr 2014;68: 1001–1007.
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–495.
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39:412–423.
   PubMed Web of Science ®Google Scholar
• Camus V, Lanic H, Kraut J, et al. Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Eur J Haematol 2014;93:9–18.
   PubMed Web of Science ®Google Scholar
• Lanic H, Kraut-Tauzia J, Modzelewski R, et al. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 2014;55:817–823.
   PubMed Web of Science ®Google Scholar
• Marti A, Marcos A, Martinez JA. Obesity and immune function relationships. Obes Rev 2001;2:131–140.
   PubMedGoogle Scholar
• Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity among adults: United States, 2011-2012. NCHS Data Brief2013:1–8.
   Google Scholar
• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood2006;107:265–276.
   Google Scholar
• Willett EV, Morton LM, Hartge P, et al. Non-Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph Consortium. Int J Cancer 2008;122:2062–2070.
   PubMed Web of Science ®Google Scholar
• Larsson SC, Wolk A. Body mass index and risk of non-Hodgkin's and Hodgkin's lymphoma: a meta-analysis of prospective studies. Eur J Cancer 2011;47:2422–2430.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Ingham RR, Reagan JL, et al. Obesity is associated with increased relative risk of diffuse large B-cell lymphoma: a meta-analysis of observational studies. Clin Lymphoma Myeloma Leuk 2014;14:122–130.
   PubMed Web of Science ®Google Scholar
• Bertrand KA, Giovannucci E, Zhang SM, et al. A prospective analysis of body size during childhood, adolescence, and adulthood and risk of non-Hodgkin lymphoma. Cancer Prev Res (Phila) 2013;6:864–873.
   PubMed Web of Science ®Google Scholar
• Maskarinec G, Erber E, Gill J, et al. Overweight and obesity at different times in life as risk factors for non-Hodgkin's lymphoma: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2008;17: 196–203.
   PubMed Web of Science ®Google Scholar
• Kelly JL, Fredericksen ZS, Liebow M, et al. The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender. Ann Epidemiol 2012;22:855–862.
   PubMed Web of Science ®Google Scholar
• Britton JA, Khan AE, Rohrmann S, et al. Anthropometric characteristics and non-Hodgkin's lymphoma and multiple myeloma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Haematologica 2008;93:1666–1677.
   PubMed Web of Science ®Google Scholar
• Patel AV, Diver WR, Teras LR, et al. Body mass index, height and risk of lymphoid neoplasms in a large United States cohort. Leuk Lymphoma 2013;54:1221–1227.
   PubMed Web of Science ®Google Scholar
• Pylypchuk RD, Schouten LJ, Goldbohm RA, et al. Body mass index, height, and risk of lymphatic malignancies: a prospective cohort study. Am J Epidemiol 2009;170:297–307.
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Kricker A, Paltiel O, et al. Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma:the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014;2014:15–25.
   PubMedGoogle Scholar
• Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneity among non-hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014;2014:130–144.
   PubMedGoogle Scholar
• Bradbury KE, Appleby PN, Key TJ. Fruit, vegetable, and fiber intake in relation to cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Clin Nutr 2014;100:394S–398S.
   PubMed Web of Science ®Google Scholar
• Ollberding NJ, Aschebrook-Kilfoy B, Caces DB, et al. Dietary patterns and the risk of non-Hodgkin lymphoma. Public Health Nutr 2014;17:1531–1537.
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625–1638.
   PubMed Web of Science ®Google Scholar
• Chiu BC, Gapstur SM, Greenland P, et al. Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev 2006;15:2348–2354.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zheng T, Lan Q, et al. Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood 2011;117:585–590.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zheng T, Lan Q, et al. Polymorphisms in DNA repair pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Am J Hematol 2013;88:606–611.
   PubMed Web of Science ®Google Scholar
• Willett EV, Skibola CF, Adamson P, et al. Non-Hodgkin's lymphoma, obesity and energy homeostasis polymorphisms. Br J Cancer 2005;93:811–816.
   PubMed Web of Science ®Google Scholar
• Carson KR, Bartlett NL, McDonald JR, et al. Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J Clin Oncol 2012;30:3217–3222.
   PubMed Web of Science ®Google Scholar
• Jones JA, Fayad LE, Elting LS, et al. Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2010;51:1649–1657.
   PubMed Web of Science ®Google Scholar
• Han X, Stevens J, Bradshaw PT. Body mass index, weight change, and survival in non-Hodgkin lymphoma patients in Connecticut women. Nutr Cancer 2013;65:43–50.
   PubMed Web of Science ®Google Scholar
• Weiss L, Melchardt T, Habringer S, et al. Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Ann Oncol 2014;25:171–176.
   PubMed Web of Science ®Google Scholar
• Park S, Han B, Cho JW, et al. Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Nutr Cancer 2014;66:225–233.
   PubMed Web of Science ®Google Scholar
• Geyer SM, Morton LM, Habermann TM, et al. Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study. Cancer 2010;116:2993–3000.
   PubMed Web of Science ®Google Scholar
• Tarella C, Caracciolo D, Gavarotti P, et al. Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft. Bone Marrow Transplant 2000;26:1185–1191.
   PubMed Web of Science ®Google Scholar
• Muller C, Murawski N, Wiesen MH, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 2012;119:3276–3284.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Mounier N, Delmer A, et al. Impact of BMI and gender on outcomes in DLBCL patients treated with R-CHOP: a pooled study from the LYSA. Lymphoma 2014; in press.
   Google Scholar
• Hong F, Habermann TM, Gordon LI, et al. The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Ann Oncol 2014;25:669–674.
   PubMed Web of Science ®Google Scholar
• Bachmann J, Heiligensetzer M, Krakowski-Roosen H, et al. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 2008;12:1193–1201.
   PubMed Web of Science ®Google Scholar
• Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69:491–497.
   Google Scholar
• Moses AW, Slater C, Preston T, et al. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 2004;90: 996–1002.
   PubMed Web of Science ®Google Scholar
• Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010;21:1594–1598.
   PubMed Web of Science ®Google Scholar
• Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 2007;13:3264–3268.
   PubMed Web of Science ®Google Scholar
• Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009;15:2920–2926.
   PubMed Web of Science ®Google Scholar
• Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes:estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 2004;97:2333–2338.
   PubMed Web of Science ®Google Scholar
• Chu M, Lieffers J, Belch A, et al. Aggressive non-Hodgkin lymphoma: predictive value of sarcopenia and skeletal muscle density on prognosis with rituximab containing therapy. Blood 2013; 122(Suppl. 1): Abstract 3023.
   Web of Science ®Google Scholar
• Antoun S, Lanoy E, Iacovelli R, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer 2013;119:3377–3384.
   PubMed Web of Science ®Google Scholar
• Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005;55:241–252.
   PubMed Web of Science ®Google Scholar
• Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000;5:224–237.
   PubMedGoogle Scholar
• Folstein MF, Folstein SE, McHugh PR.“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
   PubMed Web of Science ®Google Scholar
• Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914–919.
   Google Scholar
• Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179–186.
   PubMed Web of Science ®Google Scholar
• Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982;17:37–49.
   PubMed Web of Science ®Google Scholar
• Kaiser MJ, Bauer JM, Ramsch C, et al. Validation of the Mini Nutritional Assessment short-form (MNA-SF): a practical tool for identification of nutritional status. J Nutr Health Aging 2009;13: 782–788.
   PubMed Web of Science ®Google Scholar
• Gunzelmann T, Hessel A, Geyer M, et al [Coping with disease in the elderly - the effect of perceived control, subjective morbidity, social support and socio-demographic variables]. Z Gerontol Geriatr 1999;32:238–245.
   PubMed Web of Science ®Google Scholar
• Hamaker ME, Mitrovic M, Stauder R. The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy. Ann Hematol 2014; 93:1031–1040.
   PubMed Web of Science ®Google Scholar
• Soubeyran P, Bellera C, Gregoire F. Validation of a screening test for elderly patients in oncology. J Clin Oncol 2008;26(Suppl.): Abstract 20568.
   Google Scholar
• Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992;41:237–248.
   PubMed Web of Science ®Google Scholar
• Kenis C, Bron D, Libert Y, et al. Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. Ann Oncol 2013;24:1306–1312.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460–468.
   PubMed Web of Science ®Google Scholar
• Drake MT, Maurer MJ, Link BK, et al. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol 2010;28: 4191–4198.
   PubMed Web of Science ®Google Scholar
• Bittenbring JT, Neumann F, Altmann B, et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol 2014;32:3242–3248.
   PubMed Web of Science ®Google Scholar
• Wagatsuma A, Sakuma K. Vitamin D signaling in myogenesis: potential for treatment of sarcopenia. Biomed Res Int 2014;2014:121254.
   PubMed Web of Science ®Google Scholar
• Soubeyran P, Fonck M, Blanc-Bisson C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 2012;30:1829–1834.
   PubMed Web of Science ®Google Scholar
• Cartron G, Trappe RU, Solal-Celigny P, et al. Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res 2011;17:19–30.
   PubMed Web of Science ®Google Scholar
• Ng CM, Bruno R, Combs D, et al. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005;45:792–801.
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010;49:71–87.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol 1988;6:1321–1327.
   PubMed Web of Science ®Google Scholar
• Baker SD, van Schaik RH, Rivory LP, et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004;10:8341–8350.
   PubMed Web of Science ®Google Scholar
• Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012;30:1553–1561.
   PubMed Web of Science ®Google Scholar
• Tao W, Lagergren J. Clinical management of obese patients with cancer. Nat Rev Clin Oncol 2013;10:519–533.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Sparreboom A. Appropriate chemotherapy dosing in obese patients with cancer. Nat Rev Clin Oncol 2013;10:664.
   PubMed Web of Science ®Google Scholar
• Courneya KS, Sellar CM, Stevinson C, et al. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol 2009;27: 4605–4612.
   PubMed Web of Science ®Google Scholar
• Courneya K, Sellar C, Stevinson C, et al. Moderator effects in a randomized controlled trial of exercise training in lymphoma patients. Cancer Epidemiol Biomarkers Prev 2009;18:2600–2607.
   PubMed Web of Science ®Google Scholar
• Streckmann F, Kneis S, Leifert JA, et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. Ann Oncol 2014;25:493–499.
   PubMed Web of Science ®Google Scholar